Eastgate Biotech Corp.

ETBI

US2772531008

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 09:54:04 2024-04-30 EDT			5-day change	1st Jan Change
0.009 ^USD	+28.57%		-.--%	-10.00%

2021	EastGate Biotech Corp., Dr. Upadhyay Vedic Research Laboratories and ImmunoJuvenate, Inc. Enter Into a 3-way International Distribution Agreement	CI
2021	EastGate Biotech Corp. Enters into A Licensing and Distribution Agreement for Glucora	CI

EastGate Biotech Corp. Partners with EastGate Biotech Pakistan for the International Marketing Rights of Anaferon

January 30, 2020 at 09:00 am

EastGate Biotech Corp. announced on January 30, 2020, that the company along with its partner EastGate Biotech Pakistan has signed a Memorandum of Understanding (MOU) for the international marketing rights of Anaferon for the treatment of the novel 2019 Coronavirus, commonly called the Wuhan Coronavirus. Stock of the drug is immediately available and EastGate Pakistan is in discussions with various interested parties.

Latest news about Eastgate Biotech Corp.

EastGate Biotech Corp., Dr. Upadhyay Vedic Research Laboratories and ImmunoJuvenate, Inc. Enter Into a 3-way International Distribution Agreement	21-05-17	CI
EastGate Biotech Corp. Enters into A Licensing and Distribution Agreement for Glucora	21-03-08	CI
EastGate Biotech Corp. and EastGate Biotech Pakistan Expands its Collaboration in Advancing the Development of a New Vaccine Against COVID-19	20-02-18	CI
Eastgate Biotech Corp. Announces Phase 3 Clinical Trials of Insurgin	20-02-05	CI
EastGate Biotech Corp. Partners with EastGate Biotech Pakistan for the International Marketing Rights of Anaferon	20-01-30	CI
EastGate Biotech Corp Expands Pipeline to Alzheimer’S Disease Using Its Alternative Insulin Delivery Platform	19-11-14	CI
Eastgate Biotech Corp. Announces Expansion and Restructuring of Joint Venture with Its Partner in Pakistan	19-10-09	CI
EastGate Biotech Receives Regulatory Approval to Initiate a Phase III 90-day Clinical Trial on Insugin, Its Liquid Insulin Mouth Rinse Solution	19-09-25	CI
Eastgate Biotech Corp. Appoints Bill Abajian as Chief Operating Officer	19-09-04	CI
EastGate Biotech Corp Announces It Has Filed an Application with the Drug Regulatory Authority of Pakistan and Ministry of National Health Services to Initiate A Phase Iii Clinical Study for Insugin	19-06-26	CI
Eastgate Biotech Announces Preparation to Initiate Phase III Clinical Trials on Insugin	19-05-15	CI
EastGate Biotech Announces Positive Phase II Clinical Results of its Innovative Liquid Insulin Mouth Rinse Solution for Type 2 Diabetes	19-04-24	CI
Eastgate Biotech Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2017	19-03-04	CI
EastGate Biotech Enters into Licensing Agreement with Nico Innovapharma	18-08-28	CI
Eastgate Biotech Corp. announced that it expects to receive $2 million in funding from Nico Innovagroup S.r.l.	18-08-09	CI
Eastgate Biotech Corp. announced that it has received $0.45 million in funding	18-04-19	CI
EastGate Biotech Corp. Enters into a Memorandum of Understanding with Genluiching Mining Corporation and AAH International Associates Inc	18-03-18	CI
Eastgate Biotech Corp. announced that it expects to receive $5.8 million in funding	18-03-12	CI
Eastgate Biotech Corp. Enters into Joint Venture with AC Nova Technologies Inc	17-04-04	CI
Eastgate Biotech Corp. entered into a purchase and sale agreement to acquire OMNI Surgery + Anti-Aging Centre from Bill Abajian.	17-03-13	CI
EastGate Biotech Corp. Receives Large Order for Glucora, its Natural Glucose Management Product	16-05-05	CI
EastGate Biotech Corp. Receives Repeat Purchase Order from Preferred Nutrition Inc	16-01-06	CI
Eastgate Biotech Corp. announced that it has received $0.02 million in funding	15-10-04	CI
Eastgate Biotech Corp. Announces Commencement of Activities for its Proprietary Intraoral Insulin Tablet	15-09-29	CI
Eastgate Biotech Corp. Auditor Raises 'Going Concern' Doubt	15-03-31	CI

Chart Eastgate Biotech Corp.

Duration

Period

More charts

Company Profile

EastGate Biotech Corp. is a pharmaceutical company. The Company produces and distributes nutraceuticals that are based on natural therapies and absorbed naturally by the body. The Company utilizes nanotechnologies to deliver healthy alternatives to conventional pharmaceuticals that all too often create dangerous side effects and unexpected consequences for those trying to attain and maintain healthy lives. The Companyâs products include E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze and Warts X. The Company also develops products in which the components are incorporated into vehicles containing nano-sized delivery vectors, including oil droplets (nanoemulsions), polymeric particles (nanoparticles) and the combination of polymers and lipids with surfactants (hybrid nanoparticles, nanocapsules, mixed micelles).

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
EASTGATE BIOTECH CORP.	-10.00%	9.52M
ELI LILLY AND COMPANY	+37.78%	723B
NOVO NORDISK A/S	+32.82%	598B
JOHNSON & JOHNSON	-3.51%	364B
MERCK & CO., INC.	+19.94%	331B
ABBVIE INC.	+5.14%	288B
ASTRAZENECA PLC	+16.64%	244B
ROCHE HOLDING AG	-4.13%	208B
NOVARTIS AG	+10.63%	210B
AMGEN INC.	+9.32%	169B

Other Pharmaceuticals